Loading...
01/10 00:47
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call highlights several positive elements: strong growth in Canadian and European markets, strategic international expansion, and a focus on higher-margin opportunities. The Q&A session further supports this with insights into market share gains, price stabilization, and a promising outlook for CC Pharma. Despite some challenges in the beer segment, the company's diversified strategy and international growth potential present a positive sentiment. Given the market cap, these factors suggest a likely positive stock price movement in the short term.
Q2 Net Revenue $218 million, a record high. This represents a strong performance despite headwinds.
Adjusted EBITDA $8.4 million. This reflects operational improvements and cost management.
Adjusted EPS Loss $0.02, reflecting a reverse stock split adjustment.
Adjusted Cash Operating Income $6 million, indicating positive cash flow management.
International Cannabis Revenue $20 million, a 51% sequential growth and 36% year-over-year increase. Growth driven by international market expansion and operational improvements.
Cash and Marketable Securities $292 million, with a net cash position exceeding debt by $30 million. This reflects a strengthened balance sheet.
Canadian Adult-Use Cannabis Revenue $46 million, with a 6% growth in recreational cannabis sales. Growth attributed to product mix and market leadership.
Beverage Revenue $50 million, impacted by craft beer segment headwinds and portfolio optimization efforts.
Wellness Revenue $14.6 million, flat year-over-year. Growth in HiBall and ingredient channels offset by challenges in club retail.
Distribution Revenue $85 million, a 26% year-over-year increase. Growth driven by competitive pricing, portfolio optimization, and favorable foreign exchange impacts.
Gross Margin 26%, with increases in cannabis, distribution, and wellness segments. Beverage segment margins were temporarily impacted.
Net Loss $43.5 million, a 49% improvement year-over-year. Reflects operational improvements and cost management.
New product launch: Introduced Redecan Amped Live Resin Liquid Diamond vapes in Canada, combining 80% live resin with 20% liquid diamonds for high potency and natural flavor. Entered Quebec market with Good Supply brand vapes, achieving top 3 SKU positions.
Beverage innovation: Launched non-alcoholic beverages under Montauk, 10 Barrel, and ready-to-drink canned beverages. Expanded HiBall clean energy drink to the U.K. and planned expansion to the Middle East and Africa.
Global cannabis market expansion: International cannabis revenue grew 36% YoY and 51% sequentially, driven by growth in Europe, particularly Germany, the U.K., and Poland. Expanded pharmacy reach in Germany to triple medical cannabis distribution footprint in fiscal 2026.
Beverage market expansion: Participated in the American Craft Beer Expo in Japan and gained insights for future growth. Expanded beverage business into new international markets, focusing on craft beer and non-alcoholic drinks.
Operational efficiency in beverages: Achieved $27 million in annualized cost savings in the first half of the year under Project 420, targeting $33 million by year-end.
Cannabis cultivation efficiency: Restarted outdoor cannabis grow in Cayuga, Ontario, increasing cultivation capacity to 200 metric tons annually, reducing costs and improving profit margins.
Regulatory readiness: Prepared for U.S. cannabis rescheduling to Schedule III, positioning for federally compliant medical cannabis framework. Leveraged regulatory experience and operational capabilities for immediate action.
Canadian regulatory advocacy: Advocated for modernization of Canadian cannabis regulations, including excise tax reform and integration of cannabis into healthcare, to maintain global competitiveness.
Regulatory Challenges: Ongoing permit challenges and regulatory transitions in Portugal and Germany are impacting operations. Additionally, the lack of regulatory reform in Canada, including excise tax issues and restrictions on cannabis drinks in liquor stores, poses risks to the Canadian cannabis market.
Price Compression: Continued price compression, especially in flower products, is affecting profitability in the cannabis segment.
Supply Chain and Operational Risks: Scaling back supply in the Canadian wholesale market to prioritize higher-margin international markets could lead to supply chain inefficiencies. Additionally, operational challenges in integrating acquired beverage brands and optimizing processes are ongoing.
Market Headwinds in Craft Beer: Category-wide headwinds in the craft beer segment are negatively impacting beverage revenue.
Economic and Competitive Pressures: Competitive pricing pressures in the distribution business and challenges in the club retail channel for wellness products are affecting margins and revenue.
Regulatory Uncertainty in the U.S.: Potential regulatory changes affecting hemp-derived THC products after 2026 could impact the U.S. market.
Cannabis Rescheduling in the U.S.: Tilray is prepared to act immediately on cannabis rescheduling to Schedule III in the U.S., which is expected to lead to a federally compliant medical cannabis framework. The company has the platform, regulatory experience, and leadership team in place to scale operations.
International Cannabis Revenue Growth: Tilray expects continued momentum in international cannabis revenue, particularly in Europe (Germany, U.K., Poland). The company plans to expand its global footprint and improve operational efficiency through process improvements, automation, and increased utilization of cultivation facilities.
Medical Cannabis Distribution Expansion: Tilray aims to triple its medical cannabis distribution footprint in fiscal 2026 by expanding its pharmacy reach in Germany and leveraging strategic partnerships.
Canadian Cannabis Market: Tilray plans to elevate its Canadian cannabis business in the second half of 2026 and beyond by focusing on product mix, healthy margins, and innovation in high-growth segments like vapes and infused pre-rolls.
Beverage Business Growth: Tilray anticipates revenue improvements in the beverage segment in Q4 2026 due to spring product resets, new innovations, and strategic partnerships. The company is also prepared to produce and sell THC beverages in the U.S. if federally legalized.
Wellness Business Expansion: Tilray plans to expand its wellness business by focusing on value-added innovation, high-protein products, and clean energy drinks. The company is also exploring international growth opportunities in Asia and North America.
Adjusted EBITDA Guidance: Tilray reaffirms its fiscal 2026 adjusted EBITDA guidance of $62 million to $72 million.
The selected topic was not discussed during the call.
Earnings results show strong financial performance with significant growth in gross profit, EBITDA, and cash position. The successful app launch and international expansion plans further support a positive outlook. Despite some uncertainties in guidance, the overall sentiment from the Q&A is optimistic, with plans for store openings and margin expansion. Given the company's market cap, the stock is likely to experience a positive movement between 2% to 8% over the next two weeks.
The earnings call highlights several positive elements: strong growth in Canadian and European markets, strategic international expansion, and a focus on higher-margin opportunities. The Q&A session further supports this with insights into market share gains, price stabilization, and a promising outlook for CC Pharma. Despite some challenges in the beer segment, the company's diversified strategy and international growth potential present a positive sentiment. Given the market cap, these factors suggest a likely positive stock price movement in the short term.
The earnings call summary reveals positive financial performance with revenue growth across segments, improved cash flow, and strong liquidity. The Q&A section highlights management's proactive strategies in addressing international growth challenges, potential U.S. market opportunities, and leveraging digital assets. Despite some unclear responses, the overall sentiment is positive, supported by market expansion plans, particularly in Europe and the U.S. The market cap suggests moderate volatility, leading to a prediction of a 2% to 8% stock price increase over the next two weeks.
The earnings call highlights strong financial metrics such as a 200-basis point margin increase and reduced debt, complemented by optimistic guidance and strategic initiatives like Project 420. Despite some shipment delays, the outlook for international markets and potential regulatory changes are favorable. The Q&A section revealed optimism in market expansion and cost-saving measures, although some management responses were vague. Given the small-cap nature of the company, the positive elements are likely to lead to a stock price increase in the 2% to 8% range over the next two weeks.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
